GAITHERSBURG, MD, Hememics Biotechnologies announced today the closing of a $2 million Seed 2 financing round.
Hememics Biotechnologies, developer of first-in-class, handheld, multiplexed biosensor platform that can test antibodies, antigens and molecular targets simultaneously, announced today the closing of a $2 million Seed 2 financing round. Participants of this round include a strategic investor, existing investors and Maryland Technology Development Corporation (TEDCO).
Hememics uniquely uses graphene-based sensors with our patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed - whether it is a farm, emergency room or battlefield. Our rugged, low-cost platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors. Our sensors can be individually programmed to detect molecular, antigen and antibody targets. We put a whole lab in your hand so you can make decisions when and wherever necessary - simplifying workflows with results within minutes.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about